Twist, Kriya partner to discover novel antibodies

By The Science Advisory Board staff writers

March 11, 2022 -- Twist Bioscience and Kriya Therapeutics have entered into an antibody discovery agreement for antibodies delivered using adeno-associated viral gene therapy in therapeutic oncology applications.

Twist Biopharma, a division of Twist Bioscience, expects to leverage its antibody discovery and optimization platform to discover novel antibodies against specific targets of interest that will be engineered into Kriya's proprietary gene therapy technology platform for durable and targeted delivery, the company said.

No financial details of the agreement were disclosed.


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.